Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Trastuzumab Biosimilar Approved by the FDA
December 4th 2017Trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which is co-developed by Mylan and Biocon, has just been approved by the FDA for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma, the same indications as trastuzumab.
Combination Approved for Metastatic or Advanced Breast Cancer Treatment
November 15th 2017The FDA has approved fulvestrant (Faslodex) for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) to treat patients with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy.
Disparity in US Breast Cancer Mortality
November 14th 2017Breast cancer, the most common cancer diagnosed in women in the United States, is the second leading cause of cancer death among women after lung cancer. To track trends in disease incidence, mortality, and survival the American Cancer Society (ACS) analyzes data every 2 years.
Significant Rate of Febrile Neutropenia Seen in CDK 4/6 Inhibitor Based Regimens
November 6th 2017Cyclin D–dependent kinase (CDK) 4/6 inhibitors have proven to be effective treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. But, much like many cancer therapies, there are challenges when it comes to toxicity.
Expert Discusses the Present and Future of Genetic Testing in Breast Cancer
November 2nd 2017Laura J. van’t Veer, PhD, discussed determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Abemaciclib Approved for HR+/HER2- Breast Cancer
September 28th 2017The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.
Statins, High Cholesterol May Decrease Breast Cancer Risk
September 13th 2017Can a class of drugs commonly prescribed to help lower cholesterol levels protect against breast cancer? A study recently presented at the European Society of Cardiology conference in Barcelona, Spain, offers interesting results.
Heart Problems, Fracture Risk Greater With Extended Use of Aromatase Inhibitors
September 12th 2017The authors noted that although some studies have shown improvement in breast cancer outcomes from extending treatment with AIs beyond the initial 5 years after diagnosis, there is not much research on the toxicity profile of extended use.